Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2017 Nov 23;8(1):1407203.
doi: 10.1080/20010001.2017.1407203. eCollection 2018.

Testing drug combinations to slow aging

Affiliations
Editorial

Testing drug combinations to slow aging

Warren Ladiges et al. Pathobiol Aging Age Relat Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1.
Figure 1.
Slowing aging might best be achieved by drug combinations that target multiple interactive molecular pathways. However, very little testing of drug combinations has been done because of a lack of preclinical screening paradigms. This figure demonstrates how the interaction of a prototype drug combination, rapamycin, acarbose, and SS31, can be tested for anti-aging effects in a preclinical setting using the aged mouse and a geropathology grading system.

Similar articles

Cited by

References

    1. Ladiges W. The quality control theory of aging. Pathobiol Aging Age Relat Dis. 2014;4 PubMed PMID: 24891937; PubMed Central PMCID: PMC4033319. - PMC - PubMed
    1. Wilkinson JE, Burmeister L, Brooks SV, et al. Rapamycin slows aging in mice. Aging Cell. 2012. August;11(4):675–3. - PMC - PubMed
    1. Flynn JM, O’Leary MN, Zambataro CA, et al. Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell. 2013. October;12(5):851–862. Epub 2013 Jul 7. - PMC - PubMed
    1. Harrison DE, Strong R, Allison DB, et al. Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell. 2014. April;13(2):273–282. - PMC - PubMed
    1. Dai DF, Chen T, Szeto H, et al. Mitochondrial targeted antioxidant peptide ameliorates hypertensive cardiomyopathy. J Am Coll Cardiol. 2011. June 28;58(1):73–82. - PMC - PubMed

Publication types

LinkOut - more resources